In patients randomized < 3 hours of stroke , 18-month mortality was lower in the alteplase-treated group than the control group ( 40.6 % [ 95 % CI , 42.6-52 .7 ] versus 47.8 % [ 95 % CI , 35.5-45 .3 ] ; P = 0.0434 ] .